Tokyo, July 10, 2006 (JCN) - Taiho Pharmaceutical and sanofi-aventis have signed a licensing agreement for TS-1, an anticancer agent developed by Taiho Pharmaceutical.
Under the agreement, which was announced on June 4, sanofi-aventis will receive the rights to develop and commercialize the agent worldwide, except in Japan and some Asian countries. Sanofi-aventis will make an upfront payment, milestone payments for development and royalties on futures sales to Taiho Pharmaceutical.
Going forward, sanofi-aventis will develop the agent under the name S-1 while receiving the supply from Taiho Pharmaceutical.
TS-1/S-1 is an oral pyrimidine fluoride-derived anticancer agent which has been available in Japan since 1999. It is indicated for the treatment of gastric cancer, colorectal cancer, head and neck cancer, non-small cell lung cancer and inoperable or recurrent breast cancer.
Copyright © 2013 JCN. All rights reserved. A division of Japan Corporate News Network KK.
 Company Profile |  Print |  Alerts
|
